Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Epidermal Growth Factor Receptor (EGFR) inhibitor Panitumumab for the treatment of KRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinoma

Next Previous
Trial Profile

Efficacy of Epidermal Growth Factor Receptor (EGFR) inhibitor Panitumumab for the treatment of KRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinoma

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Nov 2019 Status changed from recruiting to suspended.
    • 17 Nov 2017 Planned initiation date changed from 15 May 2017 to 1 Nov 2017.
    • 17 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top